Related Experiment Videos

Chemoprevention of spontaneous tumorigenesis in p53-knockout mice

S D Hursting1, S N Perkins, D C Haines

  • 1Laboratory of Nutritional and Molecular Regulation, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702-1201, USA.

Cancer Research
|September 15, 1995
PubMed

Insights

Dehydroepiandrosterone (DHEA) delayed spontaneous tumor development and mortality in p53-knockout mice. Other tested cancer-chemopreventive agents did not affect tumor progression in this model.

Area of Science:

  • Oncology
  • Cancer Research
  • Molecular Biology

Background:

  • The p53 tumor suppressor gene is crucial for preventing cancer.
  • Loss of p53 function increases susceptibility to spontaneous tumorigenesis.
  • Cancer-chemopreventive agents are being investigated to mitigate cancer risk.

Purpose of the Study:

  • To evaluate the efficacy of dehydroepiandrosterone (DHEA), quercetin, d-limonene, and all-trans retinoic acid in modulating spontaneous tumor development.
  • To determine if p53-knockout (p53-/-) mice are a suitable model for testing cancer-chemopreventive strategies.

Main Methods:

  • Spontaneous tumorigenesis was assessed in male p53-/- mice.
  • Mice were treated with DHEA, quercetin, d-limonene, or all-trans retinoic acid.
  • Tumor development and mortality rates were compared to untreated control groups.

Main Results:

  • DHEA treatment significantly delayed the onset of spontaneous tumors, particularly lymphomas, and reduced subsequent mortality in p53-/- mice (P < 0.01).
  • Quercetin, d-limonene, and all-trans retinoic acid did not show any significant effect on spontaneous tumor development in this model.
  • These findings highlight DHEA's potential role in delaying cancer progression.

Conclusions:

  • Dehydroepiandrosterone (DHEA) demonstrates a chemopreventive effect by delaying tumorigenesis in p53-/- mice.
  • The p53-/- mouse model is validated as a useful platform for evaluating cancer-chemopreventive agents targeting loss of p53 function.
  • Further research into DHEA and similar compounds may offer strategies to counteract the heightened cancer risk associated with p53 deficiency.

Related Concept Videos